Mario A. Eisenberger
Johns Hopkins University · 743 works · 45,554 citations · h-index 90
Top works
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis
- Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
- Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
- Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer
- Localized Prostate Cancer
- Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone
- Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer